- Home
- FULT vs PTGX Comparison
FULT vs PTGX Comparison
Compare FULT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULT
- PTGX
- Stock Information
- Founded
- FULT 1882
- PTGX 2006
- Country
- FULT United States
- PTGX United States
- Employees
- FULT N/A
- PTGX N/A
- Industry
- FULT Major Banks
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- FULT Finance
- PTGX Health Care
- Exchange
- FULT Nasdaq
- PTGX Nasdaq
- Market Cap
- FULT 2.8B
- PTGX 2.8B
- IPO Year
- FULT N/A
- PTGX 2016
- Fundamental
- Price
- FULT $17.44
- PTGX $42.97
- Analyst Decision
- FULT Hold
- PTGX Strong Buy
- Analyst Count
- FULT 5
- PTGX 8
- Target Price
- FULT $18.70
- PTGX $66.50
- AVG Volume (30 Days)
- FULT 1.5M
- PTGX 990.2K
- Earning Date
- FULT 04-15-2025
- PTGX 05-06-2025
- Dividend Yield
- FULT 4.13%
- PTGX N/A
- EPS Growth
- FULT N/A
- PTGX N/A
- EPS
- FULT 1.57
- PTGX 0.86
- Revenue
- FULT $1,147,690,000.00
- PTGX $207,801,000.00
- Revenue This Year
- FULT N/A
- PTGX N/A
- Revenue Next Year
- FULT $4.31
- PTGX $7.13
- P/E Ratio
- FULT $11.09
- PTGX $50.68
- Revenue Growth
- FULT 11.65
- PTGX N/A
- 52 Week Low
- FULT $14.33
- PTGX $24.22
- 52 Week High
- FULT $22.49
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- FULT 57.23
- PTGX 43.08
- Support Level
- FULT $16.98
- PTGX $41.29
- Resistance Level
- FULT $17.64
- PTGX $46.12
- Average True Range (ATR)
- FULT 0.41
- PTGX 1.83
- MACD
- FULT 0.18
- PTGX -0.19
- Stochastic Oscillator
- FULT 89.01
- PTGX 27.81
About FULT Fulton Financial Corporation
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.